Balasa Dinverno & Foltz’s GSK GSK Stock Holding History

Balasa Dinverno & Foltz’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-5,346	Closed	-$253K	–	251
2020 Q1	$253K	Sell	5,346 -188	-3%	-$10K	0.03%	207
2019 Q4	$325K	Buy	5,534 +34	+0.6%	+$1.89K	0.03%	202
2019 Q3	$293K	Buy	5,500 +61	+1%	+$3.14K	0.03%	191
2019 Q2	$272K	Buy	5,439 +41	+0.8%	+$2.06K	0.03%	196
2019 Q1	$282K	Sell	5,398 -91	-2%	-$4.55K	0.03%	195
2018 Q4	$262K	Hold	5,489	–	–	0.03%	185
2018 Q3	$276K	Hold	5,489	–	–	0.03%	200
2018 Q2	$277K	Hold	5,489	–	–	0.04%	184
2018 Q1	$268K	Sell	5,489 -65	-1%	-$3.03K	0.04%	181
2017 Q4	$246K	Hold	5,554	–	–	0.04%	190
2017 Q3	$282K	Hold	5,554	–	–	0.04%	169
2017 Q2	$299K	Sell	5,554 -70	-1%	-$3.73K	0.05%	164
2017 Q1	$296K	Sell	5,624 -354	-6%	-$18K	0.05%	161
2016 Q4	$288K	Hold	5,978	–	–	0.05%	148
2016 Q3	$322K	Hold	5,978	–	–	0.06%	128
2016 Q2	$324K	Sell	5,978 -77	-1%	-$4.06K	0.06%	129
2016 Q1	$307K	Hold	6,055	–	–	0.05%	131
2015 Q4	$305K	Sell	6,055 -72	-1%	-$3.67K	0.05%	150
2015 Q3	$294K	Buy	6,127 +72	+1%	+$3.75K	0.05%	142
2015 Q2	$315K	Sell	6,055 -47	-0.8%	-$2.65K	0.05%	137
2015 Q1	$352K	Sell	6,102 -135	-2%	-$7.74K	0.05%	123
2014 Q4	$333K	Hold	6,237	–	–	0.05%	135
2014 Q3	$358K	Hold	6,237	–	–	0.05%	110
2014 Q2	$417K	Hold	6,237	–	–	0.05%	92
2014 Q1	$417K	Sell	6,237 -41	-0.7%	-$2.77K	0.05%	89
2013 Q4	$419K	Sell	6,278 -32	-0.5%	-$2.08K	0.06%	85
2013 Q3	$396K	Hold	6,310	–	–	0.07%	75
2013 Q2	$394K	Buy	+6,310	New	+$400K	0.07%	68

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Balasa Dinverno & Foltz's GSK Position: Q2 2020 in Review

Balasa Dinverno & Foltz sold out of GSK (GSK) in Q2 2020, closing a stake of 5,346 shares — an estimated $253K sold.

Balasa Dinverno & Foltz first reported a position in GSK in Q2 2013 and held it in 28 quarters. The position peaked at $419K in Q4 2013. 840 funds tracked by Wall St. Rank hold GSK as of Q2 2020.

Balasa Dinverno & Foltz reported no remaining GSK position as of Q2 2020 after selling out during the quarter.
Balasa Dinverno & Foltz sold 5,346 GSK shares in Q2 2020, an estimated $253K.
Balasa Dinverno & Foltz first reported a position in GSK in Q2 2013 and held it in 28 quarters.
Balasa Dinverno & Foltz's GSK position peaked at $419K in Q4 2013.
840 funds tracked by Wall St. Rank held GSK as of Q2 2020.

Based on Balasa Dinverno & Foltz's 13F filing for Q2 2020, filed 7 Aug 2020.